Incannex Healthcare Inc. (IXHL) Fair Value 2026

IXHL · Pharmaceutical Preparations ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.7 /10

32 fundamental signals · 9 models active

Value Trap Risk

— (—/100)

Quick Summary — As of 2026-07-15, Incannex Healthcare Inc. (IXHL) trades at $3.23, approximately 26% below CirclFi’s Bayesian DCF fair value of $4.34. QOC: 5.7/10. 9/13 models active.

Key Facts

Ticker
IXHL
Price
$3.23
Quality Score
5.7/10
Value Trap Risk
—/100
Models Active
9/13
Last Updated
Strength: Dynamic NAV suggests +112.5% upside with 46% confidence
Risk: Limited model coverage (9/13) may reduce confidence

Is Incannex Healthcare Inc. (IXHL) Undervalued or Overvalued in 2026?

According to CirclFi’s 9-model valuation engine, Incannex Healthcare Inc. (IXHL) appears undervalued as of : the median of 9 independent fair value estimates is $4.60, 42.5% above the current price of $3.23. Estimates range from $1.16 to $6.86. IXHL scores 5.7/10 on fundamental quality and —/100 on value-trap risk.

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Incannex Healthcare Inc. Stock in 2026? →

Valuation Matrix

9 Intrinsic Value Models vs. Current Price ($3.23)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Low Conviction
 $4.34 +34.4%
CUCE Ensemble
Low Conviction
 $4.60 +42.5%
First Chicago
Medium Conviction
 $1.16 -64.1%
Dynamic NAV
Medium Conviction
 $6.86 +112.5%

Unlock the Full Matrix

Access 5 additional models including ML-RIV, PWERM, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 9 Models →

Cancel anytime · No contracts · Instant access

What Is Incannex Healthcare Inc. (IXHL) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the weight of evidence tilts decidedly bullish for Incannex Healthcare Inc.. Trading at $3.23 against an estimated intrinsic value of $4.61, 7 of 9 active models flag meaningful upside of +42.7% on average. The most optimistic model, Dynamic NAV, places fair value at $6.86 (+112.5%), while First Chicago — the most conservative — estimates $1.16 (-64.1%). This +176.6% gap reflects genuine analytical uncertainty about Incannex Healthcare Inc.'s intrinsic worth.

What Do the Models Say About IXHL?

9 of 13 models are currently active for IXHL. Of these, 7 models suggest upside while 2 models suggest overvaluation. The Bayesian DCF estimates IXHL's intrinsic value at $4.34, implying +34.4% upside from the current price. See which stocks rank higher →

How Does IXHL Rank in Pharmaceutical Preparations?

Among 431 Pharmaceutical Preparations stocks, IXHL ranks #149 by Quality of Company score. CirclFi's QOC score of 5.7/10 evaluates 32 fundamental signals. A score of 5.7 reflects mixed fundamentals.

See all Most Undervalued Pharmaceutical Preparations Stocks →

As a pharmaceutical industry, Incannex Healthcare Inc. operates in a sector where FDA approval probability is a critical driver of valuation. Investors evaluating IXHL should weigh these sector-specific dynamics alongside our model-derived fair values.

Is IXHL a Value Trap?

The Value Trap algorithm is not active for IXHL. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

9 of 13 models are active for Incannex Healthcare Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Incannex Healthcare Inc.'s fundamental quality profile registers 5.7/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +176.6% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every IXHL valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across IXHL's 9 active models, average confidence is 27%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Incannex Healthcare Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Pharmaceutical Preparations Stocks Should You Also Analyze?

8 related Pharmaceutical Preparations stocks with 13-model coverage

AZNAstraZeneca PLCQOC 10.0CPRXCatalyst Pharmaceuticals, Inc.QOC 10.0HRMYHarmony Biosciences Holdings, IQOC 10.0NVONovo Nordisk A/SQOC 10.0SIGASIGA Technologies Inc.QOC 10.0UTHRUnited Therapeutics CorporationQOC 10.0ZTSZoetis Inc.QOC 10.0RDYDr. Reddy's Laboratories LtdQOC 9.9

Read investment analysis: AZN · CPRX · HRMY · NVO · SIGA

See all Pharmaceutical Preparations stocks ranked →

Frequently Asked Questions About Incannex Healthcare Inc.

What is Incannex Healthcare Inc.'s intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Incannex Healthcare Inc. (IXHL) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $4.34. The Quality of Company score is 5.7/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is IXHL overvalued or undervalued right now?

At $3.23, 7 of 9 active models suggest IXHL may be undervalued, while 2 indicate potential overvaluation. The median of all 9 fair value estimates is $4.60, 42.5% above the current price of $3.23 — a consensus view that IXHL is undervalued. The assessment depends on which methodology best fits Incannex Healthcare Inc.'s business model in Pharmaceutical Preparations.

What does a Quality of Company score of 5.7 mean for IXHL?

Incannex Healthcare Inc.'s QOC of 5.7/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on IXHL?

CirclFi analyzes IXHL with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 9 of 13 are active for this stock. Read the full methodology →

Is IXHL a value trap in 2026?

CirclFi's Value Trap algorithm does not have sufficient data for IXHL at this time. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 9-model valuation engine, Incannex Healthcare Inc. (IXHL) has a median fair value of $4.60 — 42.5% above the current price of $3.23 — as of 2026-07-15.” Source: circlfi.com/stock/IXHL/ · Methodology

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 9 mathematical frameworks give you clarity on IXHL.

Unlock All 9 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access